Autism Disorder and Treatment Market Information: By Type (Asperger Syndrome, Pervasive Developmental Disorder, Others), by Treatment Type (Aba, Hyperbaric Oxygen Therapy, and Others), by Drug (SSRIs, Anti-Convulsant, Others) – Global Forecast Till 2027

Autism Spectrum Disorder (ASD) can be defined as a composite term that includes a range of conditions that are caused by challenges with repetitive behaviors, social skills, speech & nonverbal communication, along with unique strengths and differences. The treatment for ASD is becoming a strong market. A new report on the global autism disorder and treatment market, published by Market Research Future (MRFR), prophecizes that this market can notice progress at 4.37% CAGR during the forecast period (2017-2023).

The vital market driving factors for the global autism disorder and treatment market growth are raising awareness about autism among the patient population and rising prevalence of autism and Pervasive Developmental Disorder (PDD). Other global autism disorder and treatment market driving factors that can elevate the market growth include expected approvals of various off-label treatment therapies by the Food and Drug Association (FDA), innovations in treatment, increasing research & development (R&D), and initiatives taken by the government of various nations. Some factors impeding the market growth are unknown etiology as well as the pathophysiology of ASD and a weak pipeline of drugs for autism disorder.

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/1605

Market Segmentation

The global autism disorder and treatment market segmentation encompasses drugs, type, and treatment type. MRFR’s research on the market highlights many facets of the market in-depth.

Based on drugs, this market has been segmented into anti-convulsant drugs, anti-psychotic drugs, selective serotonin reuptake inhibitors (SSRIs), and stimulants. The antipsychotic drugs segment has been sub-segmented into Abilify (aripiprazole) and risperidone. The antipsychotic drugs segment has the maximum market coverage and is expected to grow at 3.95% CAGR during the forecast period.

By type, the market includes Asperger syndrome, pervasive developmental disorder, and others. During the forecast period, the pervasive developmental disorder is expected to grow at 4.73% CAGR, as it is the largest market segment.

Regarding treatment type, the market has been segmented into the applied behavioral analysis (ABA), chelation therapy, hyperbaric oxygen therapy, oxytocin therapy, and others. ABA is the largest and market segment, and during the forecast period, it is expected to grow at 4.82% CAGR.

Regional Segmentation

A geographical outlining of the global autism disorder and treatment market covers the Americas (North America & South America), Europe, APAC (Asia Pacific), and the Middle East & Africa (MEA).

The Americas region commands the maximum market share in the global market, followed by Europe. The presence of major market players, availability of advanced medical facilities, and technological advancement make North America a bigger market compared to South America. The market in North America is growing due to the approval, and it expects the launch of the atypical anti-psychotic such as Latuda and Namenda, with their high sales in the USA. Many autism cases have been detected in North America. After the USA, Canada generates maximum sales as well as revenue with regards to autism treatment and drugs.

Europe is the second-largest regional market as after North America; maximum major market players are based in Europe. The countries that can become important markets during the forecast period are France, Germany, Italy, Spain, and the UK. Research on the remaining countries in Western Europe featured in this report estimate the strong addition to market revenue from various other countries in this region, with some sizable market revenue from Eastern Europe.

During the forecast period, the market in the Asia Pacific region can be the fastest growing regional market. In this region, the factors contributing to the market growth include the expansion of diagnostic criteria, increasing prevalence of ASD, more awareness, better diagnostic tools, and improved reporting. The countries that can be crucial markets in this region are Australia, China, India, Japan, and South Korea.

During the forecast period, the market in the MEA region can grow steadily due to slow progress in the improvement of healthcare infrastructure. The countries that can be decent markets in this region are Kuwait, Oman, Saudi Arabia, Qatar, and the UAE.

Key Players

Big players in the global autism disorder and treatment market are Allergan (Ireland), Bristol-Myers Squibb (USA), Consern Pharma Private Limited (India), Coronis Partners Ltd. (Israel), Curemark LLC (USA), Eli Lilly & Company (USA), Heptares Therapeutics Limited (UK), Intra-Cellular Therapies Inc. (USA), Johnson & Johnson Services Inc. (USA), Merck & CO Inc. (USA), Novartis AG (Switzerland), Otsuka Holdings Co. Ltd. (Japan), Pfizer Inc. (USA), Saniona AB (Denmark), and Teva Pharmaceutical Industries Ltd. (Israel).

Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/autism-disorder-and-treatment-market-1605

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact:

Akash Anand

Market Research Future

+1 646 845 9312

Email: [email protected]